1. Home
  2. NVG vs NVCR Comparison

NVG vs NVCR Comparison

Compare NVG & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVG
  • NVCR
  • Stock Information
  • Founded
  • NVG 1999
  • NVCR 2000
  • Country
  • NVG United States
  • NVCR Switzerland
  • Employees
  • NVG N/A
  • NVCR N/A
  • Industry
  • NVG Investment Managers
  • NVCR Medical/Dental Instruments
  • Sector
  • NVG Finance
  • NVCR Health Care
  • Exchange
  • NVG Nasdaq
  • NVCR Nasdaq
  • Market Cap
  • NVG N/A
  • NVCR 1.9B
  • IPO Year
  • NVG N/A
  • NVCR 2015
  • Fundamental
  • Price
  • NVG $12.01
  • NVCR $17.44
  • Analyst Decision
  • NVG
  • NVCR Buy
  • Analyst Count
  • NVG 0
  • NVCR 6
  • Target Price
  • NVG N/A
  • NVCR $32.83
  • AVG Volume (30 Days)
  • NVG 568.8K
  • NVCR 861.0K
  • Earning Date
  • NVG 01-01-0001
  • NVCR 04-24-2025
  • Dividend Yield
  • NVG 4.65%
  • NVCR N/A
  • EPS Growth
  • NVG N/A
  • NVCR N/A
  • EPS
  • NVG N/A
  • NVCR N/A
  • Revenue
  • NVG N/A
  • NVCR $621,711,000.00
  • Revenue This Year
  • NVG N/A
  • NVCR $2.90
  • Revenue Next Year
  • NVG N/A
  • NVCR $10.47
  • P/E Ratio
  • NVG N/A
  • NVCR N/A
  • Revenue Growth
  • NVG N/A
  • NVCR 18.27
  • 52 Week Low
  • NVG $9.68
  • NVCR $14.17
  • 52 Week High
  • NVG $12.21
  • NVCR $34.13
  • Technical
  • Relative Strength Index (RSI)
  • NVG 54.33
  • NVCR 48.61
  • Support Level
  • NVG $11.73
  • NVCR $16.19
  • Resistance Level
  • NVG $12.12
  • NVCR $18.52
  • Average True Range (ATR)
  • NVG 0.14
  • NVCR 0.85
  • MACD
  • NVG 0.06
  • NVCR 0.06
  • Stochastic Oscillator
  • NVG 85.90
  • NVCR 54.82

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: